Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. 🚀 Unusual movers, 🎞️ market snapshot, and 💥 crucial news – we've got it all!

Happening Today

✓ 10:30 AM ET – Crude Oil Inventories

✓ 02:00 PM ET – FOMC Economic Projections

✓ 02:00 PM ET – FOMC Statement

✓ 02:00 PM ET – Fed Interest Rate Decision

✓ 02:30 PM ET – FOMC Press Conference

Daily Quote

You can't control the market, but you can control your reaction to it. - Benjamin Graham

PREMARKET SNAPSHOT 📈

Stock futures are pointing higher this morning, with the Dow Jones leading the pack with a gain of 0.83%.

SECTOR SNAPSHOT ✨

Energy powers ahead (1.08%) in a positive market. Most sectors climb, with Utilities (0.92%) and Industrials (0.82%) joining the rally.

Unusual Volume

📈 Ontrak Inc (OTRK) jumped 131.58% to $0.44 on a whopping 214.43 million shares traded. 

📈 Investors went wild, sending Li-Cycle Holdings Corp (LICY) stock soaring 22.73% to $1.35 on a massive volume of 93.9 million shares after the company provided business update.

📈 Abnormal activity shook C3is Inc (CISS), pushing it up 2.03% to $0.03 on a whopping 86.92 million shares traded after the company announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company of approximately $6.0 million.

📈 SCWorx Corp (WORX) stock recently closed 51.06% upper at $2.84 on substantial volume of 83.32 million shares.

📈 BYND Cannasoft Enterprises Inc (BCAN) decrease by -15.25% in a single trading session, with abnormally high trading volume of 62.38 million shares.

Premarket Movers

Important FDA 

Recently Announced

Orchard Therapeutics plc (ORTX) recently achieved FDA approval for its gene therapy, OTL-200, branded Lenmeldy, targeting children with metachromatic leukodystrophy, a significant milestone in pediatric care. This decision, announced on March 18, 2024, represents a crucial advance in addressing this debilitating condition.

Kyowa Hakko Kirin Co., Ltd.'s OTL-200 also received FDA approval for the same indication, signaling a strengthened therapeutic landscape for metachromatic leukodystrophy. This approval further emphasizes the industry's dedication to developing innovative solutions for rare diseases.

OptiNose Inc. (OPTN) secured FDA approval on March 15, 2024, for its XHANCE nasal spray, expanding its use to treat chronic rhinosinusitis in adults. This approval reflects the company's commitment to improving patient outcomes and addressing prevalent conditions affecting patients' quality of life.

Upcoming this Week

This week, Merck & Co Inc. (MRK) eagerly anticipates the FDA's decision on Sotatercept for adult patients suffering from pulmonary arterial hypertension, a condition necessitating improved treatment options

On March 27, 2024, Akebia Therapeutics, Inc. (AKBA) is awaiting the outcome of its resubmitted NDA for Vadadustat, aiming to provide a potential solution for managing anemia due to chronic kidney disease (CKD) in adult patients undergoing dialysis, addressing a critical unmet medical need in this population.

Lastly, on March 31, 2024, Esperion Therapeutics (ESPR) is on the edge of their seat for the FDA's decision regarding NEXLIZET, focusing on the inclusion of cardiovascular risk reduction and expansion of LDL-C lowering indications, signaling efforts to enhance cardiovascular care and patient outcomes.

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

 Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.